On July 15, 2025, Imexpharm was once again named among the Top 50 Corporate Sustainability Awards (CSA 2025), organized by Nhip Cau Dau Tu

magazine, marking another milestone in the company’s long-standing commitment to sustainable development.

This acknowledgment highlights Imexpharm’s ongoing efforts to integrate sustainability into its business model, with a focus on community health, environmental protection, and transparent corporate governance.

For nearly five decades, Imexpharm has followed the guiding principle of “Connecting Science – For Community Health,” embedding ESG (Environmental, Social, and Governance) practices into its operations. The company develops healthcare solutions that meet stringent EU-GMP standards, aiming to serve both domestic and international markets while contributing to the growth of Vietnam’s pharmaceutical industry.

People’s Doctor, Pharmacist Tran Thi Dao, General Director of Imexpharm, shared: “In the face of rapid socioeconomic changes, Imexpharm remains committed to sustainable development under the vision: ‘A comprehensive healthcare ecosystem – For a healthier future community.’ This is the driving force that inspires us to continuously innovate, optimize operations, expand internationally, strengthen the supply chain, and stand side-by-side with the community on the journey to holistic well-being.”

To support its ambition of becoming a regional leader in high-tech pharmaceuticals, Imexpharm has invested heavily in production infrastructure, including 12 EU-GMP-standard production lines, and continues to boost R&D capabilities by allocating 5% of annual revenue to research. In 2024 alone, the company introduced 24 new products, including next-generation antibiotics and injectable drugs. Imexpharm currently holds 28 EU-MAs for 11 products approved in the European Union.

Its manufacturing facilities operate on a closed-loop model with strict quality control from raw materials to finished products. The company uses certified raw materials with Certificate of Suitability (CEP) and enzymatic processes for antibiotic production to minimize chemical use and environmental impact.

In waste management, Imexpharm partners with INSEE Ecocycle, part of Siam City Cement Group, to implement co-processing solutions. Green factory clusters are equipped with ISO 14001:2015-certified water systems and advanced HVAC systems. Solar power systems are already in use at the headquarters and are being rolled out at larger facilities.

Imexpharm is also expanding its therapeutic portfolio to include specialized areas such as cardiology, diabetes, neurology, and gastroenterology, with an emphasis on high-tech and knowledge-driven medicines. The goal is to improve access to affordable and effective treatment for increasingly complex health conditions.

Sustainability at Imexpharm also involves active engagement with local communities. In 2024, the company supported education initiatives worth VND755 million ($29,038) and ran free medication distribution and environmental campaigns, including tree planting and waste collection. Early this year, it donated 500 trees to the Da Lat Youth Union as part of the city's urban greening program.

On the governance front, Imexpharm has adopted International Financial Reporting Standards (IFRS) and implemented the SAP S/4HANA Cloud ERP system to improve transparency and efficiency. It is also listed on the VNSI20 Sustainable Development Index.

These combined efforts have contributed to Imexpharm’s strong financial performance. In 2024, gross revenue reached VND2,513 billion ($96.7 million), up 18.9% year-on-year. In the first five months of 2025, net revenue rose to VND1,001 billion ($38.5 million), a 25% increase, with EBITDA climbing 23% to VND211 billion ($8.12 million).

“We believe that a truly sustainable model is one that not only creates economic value but also spreads inspiration and leaves a lasting, positive impact on society – true to the philosophy that Imexpharm has always pursued: ‘1,000 years later, the lotus still blooms,’” said Pharmacist Tran Thi Dao.